Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 808

1.

Global research trends in the medical therapy of pulmonary arterial hypertension 2000-2014.

Schreiber C, Edlinger C, Eder S, Ausserwinkler M, Wernly B, Pretsch I, Jung C, Hoppe UC, Lichtenauer M.

Pulm Pharmacol Ther. 2016 May 31. pii: S1094-5539(16)30038-4. doi: 10.1016/j.pupt.2016.05.004. [Epub ahead of print]

PMID:
27259806
2.

Update on pulmonary arterial hypertension pharmacotherapy.

Velayati A, Valerio MG, Shen M, Tariq S, Lanier GM, Aronow WS.

Postgrad Med. 2016 Jun;128(5):460-73. doi: 10.1080/00325481.2016.1188664.

PMID:
27232660
3.

Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti.

Yasuda K, Minami N, Yoshikawa Y, Taketani T, Fukuda S, Yamaguchi S.

Pediatr Int. 2016 May;58(5):394-396. doi: 10.1111/ped.12831.

PMID:
27173419
4.

Effects of extrathoracic mechanical ventilation on pulmonary hypertension secondary to lung disease.

Sato Y, Saeki N, Asakura T, Aoshiba K, Kotani T.

J Anesth. 2016 Aug;30(4):663-70. doi: 10.1007/s00540-016-2172-7. Epub 2016 Apr 18.

PMID:
27090795
5.

Drugs for Pulmonary Arterial Hypertension — Project Protocol [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Feb.

6.

Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension.

Tokunaga N, Ogawa A, Ito H, Matsubara H.

J Cardiol. 2016 Mar 18. pii: S0914-5087(15)00387-1. doi: 10.1016/j.jjcc.2015.11.012. [Epub ahead of print]

PMID:
27005767
7.

Macitentan (Opsumit): For Long-Term Treatment of Pulmonary Arterial Hypertension [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.

8.

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension.

Pugliese SC, Bull TM.

Integr Blood Press Control. 2016 Jan 25;9:1-7. doi: 10.2147/IBPC.S68230. eCollection 2016. Review.

9.

Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis.

Zhang H, Li X, Huang J, Li H, Su Z, Wang J.

Medicine (Baltimore). 2016 Jan;95(4):e2575. doi: 10.1097/MD.0000000000002575. Review.

10.

Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report.

Wang G, Fan R, Ji R, Zou W, Penny DJ, Varghese NP, Fan Y.

BMC Pulm Med. 2016 Jan 22;16:17. doi: 10.1186/s12890-016-0183-7.

11.

Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.

O'Connell C, Amar D, Boucly A, Savale L, Jaïs X, Chaumais MC, Montani D, Humbert M, Simonneau G, Sitbon O.

Drug Saf. 2016 Apr;39(4):287-94. doi: 10.1007/s40264-015-0365-x. Review.

PMID:
26748508
12.

The limits of oral therapy in pulmonary arterial hypertension management.

Liu QQ, Jing ZC.

Ther Clin Risk Manag. 2015 Nov 23;11:1731-41. doi: 10.2147/TCRM.S49026. eCollection 2015. Review.

13.

Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.

Lang IM, Gaine SP.

Eur Respir Rev. 2015 Dec;24(138):630-41. doi: 10.1183/16000617.0067-2015. Review. Erratum in: Eur Respir Rev. 2016 Mar;25(139):99.

14.

An Update on the Management of Pulmonary Arterial Hypertension and the Pharmacist's Role.

Macaulay TE, Covell MB, Pogue KT.

J Pharm Pract. 2016 Feb;29(1):67-76. doi: 10.1177/0897190015615902. Epub 2015 Nov 26.

PMID:
26614770
15.

[Tunnelled central venous line-associated infections in patients with pulmonary arterial hypertension treated with intravenous prostacyclin].

Boucly A, O'Connell C, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.

Presse Med. 2016 Jan;45(1):20-8. doi: 10.1016/j.lpm.2015.10.001. Epub 2015 Nov 4. French.

PMID:
26547673
16.

Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension.

Tonelli AR, Ahmed MK, Alkukhun L, Cikach F, Aulak K, Dweik RA.

Am J Respir Crit Care Med. 2015 Oct 15;192(8):1014-6. doi: 10.1164/rccm.201506-1091LE. No abstract available.

PMID:
26469842
17.

Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series.

Bonham CA, Oldham JM, Gomberg-Maitland M, Vij R.

Chest. 2015 Oct;148(4):1055-62. doi: 10.1378/chest.14-2546.

PMID:
26437815
18.

Role of Vasodilator Testing in Pulmonary Hypertension.

Sharma A, Obiagwu C, Mezue K, Garg A, Mukherjee D, Haythe J, Shetty V, Einstein AJ.

Prog Cardiovasc Dis. 2016 Jan-Feb;58(4):425-33. doi: 10.1016/j.pcad.2015.09.006. Epub 2015 Oct 3. Review.

PMID:
26434988
19.

Inhaled treprostinil via the Tyvaso Inhalation System through a tracheostomy.

Huckaby J, Lawrence P, Center A, Simon D.

BMJ Case Rep. 2015 Sep 14;2015. pii: bcr2015211602. doi: 10.1136/bcr-2015-211602.

PMID:
26370630
20.

Early Effects of Oral Pulmonary Vasodilators in an Elderly Patient with Critical Thromboembolic Pulmonary Hypertension: A Case Report.

Okazaki H, Hata N, Shirakabe A, Tsurumi M, Shinada T, Shimizu W.

J Nippon Med Sch. 2015;82(4):206-10. doi: 10.1272/jnms.82.206.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk